PLYX
NASDAQPolaryx Therapeutics Inc.
Polaryx Therapeutics Inc. (PLYX) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. In the last 30 days Quantisnow tracked 1 wire item for PLYX, including 1 press release or news item. The most recent was published Nov 9, 2026.
Financial highlights
Full financials- Net income, FY2025
- -$8.98M
- Cash
- $11.54M
For fiscal 2025 (ended Dec 31, 2025), from SEC filings. Not investment advice.
News · 26 weeks16+100%
2026-05-172026-11-08
Mix790d
- SEC Filings3(43%)
- Other2(29%)
- Analyst1(14%)
- Leadership1(14%)
Activity · 52 weeks3025 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news
Latest news
25 items- PRPolaryx Therapeutics Activates First Clinical Trial Site for SOTERIA Phase 2 Basket Trial of PLX-200PARAMUS, N.J., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (NASDAQ:PLYX) ("Polaryx" or the "Company"), a clinical-stage biotechnology company developing novel, disease-modifying therapies for rare pediatric lysosomal storage disorders (LSDs), today announces the activation of the first clinical trial site for SOTERIA, its Phase 2 basket trial evaluating the Company's lead investigational drug candidate, PLX-200, across four rare pediatric LSDs. Boys Town National Research Hospital in Boys Town, Nebraska, where the study is being led by Isabella Herman, M.D., Ph.D., a pediatric neurologist and neurogeneticist, is now positioned to begin protocol-directed screening of eligi
- SECPolaryx Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Polaryx Therapeutics, Inc. (0002075320) (Filer)
- SECPolaryx Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Polaryx Therapeutics, Inc. (0002075320) (Filer)
- PRPolaryx Therapeutics Appoints Dr. Will Charlton as Chief Medical OfficerDr. Charlton brings over 15 years of rare disease and pediatric drug development experience including CMO and clinical development roles Appointment further strengthens clinical leadership and execution capabilities ahead of planned SOTERIA Phase 2 initiation in Q4 2026 PARAMUS, NJ, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (NASDAQ:PLYX), a clinical-stage biotechnology company developing novel, disease-modifying therapies for rare pediatric lysosomal storage disorders ("LSDs"), today announced the appointment of Will Charlton, M.D., M.A.S. as Chief Medical Officer, effective September 1, 2026. With nearly two decades of leadership experience as a Chief Medical Officer
- PRPolaryx Therapeutics Advances Operational Readiness for SOTERIA Phase 2 Basket TrialCompany on track to initiate SOTERIA trial in the second half of 2026 Clinical development activities advancing following FDA authorization, CRO engagement and Fast Track Designation across all four planned indication PARAMUS, NJ, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (NASDAQ:PLYX), a clinical-stage biotechnology company developing novel, disease-modifying therapies for rare pediatric lysosomal storage disorders ("LSDs"), today provided an operational readiness update for SOTERIA, its Phase 2 basket trial evaluating lead candidate PLX-200 across four rare pediatric LSDs. Polaryx continues to advance clinical trial start-up activities in collaboration with its cont
- SECSEC Form 10-Q filed by Polaryx Therapeutics Inc.10-Q - Polaryx Therapeutics, Inc. (0002075320) (Filer)
- ANALYSTRaymond James initiated coverage on Polaryx Therapeutics with a new price targetRaymond James initiated coverage of Polaryx Therapeutics with a rating of Strong Buy and set a new price target of $6.00
- SECSEC Form DEFA14A filed by Polaryx Therapeutics Inc.DEFA14A - Polaryx Therapeutics, Inc. (0002075320) (Filer)
- SECSEC Form DEF 14A filed by Polaryx Therapeutics Inc.DEF 14A - Polaryx Therapeutics, Inc. (0002075320) (Filer)
- SECSEC Form S-8 filed by Polaryx Therapeutics Inc.S-8 - Polaryx Therapeutics, Inc. (0002075320) (Filer)
- SECPolaryx Therapeutics Inc. filed SEC Form 8-K: Leadership Update8-K - Polaryx Therapeutics, Inc. (0002075320) (Filer)
- SECPolaryx Therapeutics Inc. filed SEC Form 8-K: Shareholder Director Nominations, Other Events8-K - Polaryx Therapeutics, Inc. (0002075320) (Filer)
- ANALYSTH.C. Wainwright initiated coverage on Polaryx Therapeutics with a new price targetH.C. Wainwright initiated coverage of Polaryx Therapeutics with a rating of Buy and set a new price target of $7.00
- INSIDERChief Executive Officer Yang Alex Keun Mo bought $360,004 worth of shares (88,453 units at $4.07) (SEC Form 4)4 - Polaryx Therapeutics, Inc. (0002075320) (Issuer)
- SECPolaryx Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Polaryx Therapeutics, Inc. (0002075320) (Filer)
- PRPolaryx Therapeutics Announces Closing of $10 Million Private Placement Equity Financing to Support Launch of SOTERIA Phase 2 Basket TrialPARAMUS, NJ, May 28, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (the "Company" or "Polaryx") (NASDAQ:PLYX), a clinical-stage biotechnology company developing novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders ("LSDs"), today announced that it has closed a private investment in public equity ("PIPE") financing resulting in proceeds of $10 million. The PIPE financing closed on May 28, 2026. The PIPE financing consisted of an aggregate of 2,502,696 shares of common stock at an average purchase price of approximately $4.00 per share. Polaryx intends to use the net proceeds from the PIPE financing, together with existing cash and cash equivalents, to f
- PRPolaryx Therapeutics Receives GHP Magazine's Healthcare & Pharmaceuticals AwardsPARAMUS, NJ, May 14, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics (NASDAQ:PLYX), a clinical-stage biotechnology company focused on developing disease-modifying therapies for rare, pediatric lysosomal storage disorders (LSDs), announces that it has been named a double winner of the 2026 GHP Magazine Healthcare & Pharmaceutical Awards as both the Best Pediatric Lysosomal Storage Disease Therapeutics 2026 - USA and the Rare Neurodegenerative Disease Drug Development Excellence Award 2026 - USA awards recipient. "While current treatments have pushed care forward for lysosomal storage disorders, children and their families still face a significant daily treatment burden," said Alex Yang, J.D.
- PRPolaryx Therapeutics to Participate in National Tay-Sachs & Allied Diseases Association Annual Family ConferencePARAMUS, NJ, April 23, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics (NASDAQ:PLYX), a clinical-stage biotechnology company focused on developing disease-modifying therapies for rare, pediatric lysosomal storage disorders (LSDs), today announced its participation in the National Tay-Sachs & Allied Diseases Association (NTSAD) Annual Family Conference, taking place April 30 through May 3, 2026, at the Hyatt Regency in Reston, Virginia. "The NTSAD Annual Family Conference is an important opportunity to connect directly with the families and advocates at the heart of the rare disease community," said Alex Yang, J.D., LL.M., Chief Executive Officer of Polaryx Therapeutics. "These interactions
- PRPolaryx Therapeutics Receives U.S. FDA Fast Track Designations for All Four Indications to be Evaluated in the SOTERIA Basket TrialPARAMUS, N.J., April 21, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (NASDAQ:PLYX), a clinical-stage biotechnology company developing disease-modifying therapies for rare pediatric LSDs, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to PLX-200 for the treatment of Juvenile Neuronal Ceroid Lipofuscinosis (JNCL/CLN3 disease), Krabbe disease (globoid cell leukodystrophy), and Sandhoff disease (GM2 gangliosidosis Type II). Following the March 2026 grant of FTD to PLX-200 in treatment of Late-Infantile Neuronal Ceroid Lipofuscinosis (LINCL/CLN2 disease), PLX-200 now holds FTD for all four prospective indications to be studied
- PRPolaryx Therapeutics Recognized with Pinnacle Award for Excellence in Pediatric CarePARAMUS, NJ, April 15, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics (NASDAQ:PLYX), a clinical-stage biotechnology company focused on developing disease-modifying therapies for rare, pediatric lysosomal storage disorders (LSDs), announces that it has been named a winner of the 2026 Pinnacle Awards for Healthcare, being selected as a Diamond honoree for Excellence in Pediatric Care. Polaryx was recognized for its innovative and scalable approach to treating lysosomal storage disorders (LSDs), a group of rare genetic diseases that cause progressive neurological decline and early mortality. Rather than developing therapies for individual conditions in isolation, the company is advancing a pl
- PRPolaryx Therapeutics To Participate In The 25th Annual Needham Virtual Healthcare ConferencePARAMUS, NJ, April 01, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (NASDAQ:PLYX), a clinical-stage biotechnology company developing novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders ("LSDs"), announces that members of the executive team will be participating in the 25th Annual Needham Virtual Healthcare Conference. Format: Polaryx management will host one-on-one investor meetings as well as a group presentation Dates: One‑on‑one meetings: Monday, April 13, 2026 through Thursday, April 16, 2026 Group presentation: Thursday, April 16, 2026 at 10:15 a.m. ET To schedule a meeting, please contact your Needham & Company, LLC representative. Live web
- PRPolaryx Therapeutics Receives FDA Fast Track Designation for PLX‑200 for Late‑Infantile Neuronal Ceroid Lipofuscinosis (CLN2 Disease)Regulatory milestone supports advancement of the SOTERIA Phase 2 basket trial evaluating PLX‑200 across multiple lysosomal storage disorders PARAMUS, NJ, March 17, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (NASDAQ:PLYX), a clinical-stage biotechnology company developing disease-modifying therapies for rare pediatric lysosomal storage disorders ("LSDs"), today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to PLX-200 for the treatment of Late-Infantile Neuronal Ceroid Lipofuscinosis (LINCL/CLN2 disease). The Fast Track program is designed to facilitate and expedite the review of therapies intended to treat serious or life-threatenin
- PRPolaryx Therapeutics Deepens Engagement with the Krabbe Disease Community Through Scientific and Patient Advocacy EventsPARAMUS, NJ, March 12, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (NASDAQ:PLYX), a clinical-stage biotechnology company developing novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders ("LSDs"), announces its participation in two upcoming events supporting the Krabbe disease community. These events reflect Polaryx's ongoing commitment to advancing research and strengthening engagement with patients, caregivers, and clinicians. 2026 Krabbe Translational Research Network Members of the Polaryx executive team, including Dr. Lisa Bollinger, Chief Medical Officer, Dr. Shrijay Vijayan, Chief Scientific and Business Development Officer, and Dr. Minsu Kang,
- PRPolaryx Therapeutics Marks Rare Disease Day, Reaffirming Commitment to Patients with Rare Pediatric Lysosomal Storage DisordersPARAMUS, NJ, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics (NASDAQ:PLYX), a clinical-stage biotechnology company developing novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders ("LSDs"), joins the global rare disease community in raising awareness and supporting patients, families, caregivers, and healthcare providers. "On Rare Disease Day, Polaryx proudly stands alongside the rare disease community - patients, families, caregivers, researchers, and advocacy partners to underscore the urgent need for new and transformative treatments," said Alex Yang, Chairman and Chief Executive Officer of Polaryx Therapeutics, Inc. "We are deeply committed to raisi
- ANALYSTMaxim Group initiated coverage on Polaryx Therapeutics with a new price targetMaxim Group initiated coverage of Polaryx Therapeutics with a rating of Buy and set a new price target of $10.00
PLYX FAQ
8 questionsWhat is the latest news on PLYX?
In the last 30 days Quantisnow tracked 1 wire item for PLYX: 1 press release or news item. The most recent was published on November 9, 2026.Is PLYX profitable?
No. Polaryx Therapeutics Inc. reported a net loss of $8.98M for fiscal 2025 (ended Dec 31, 2025).How much cash and debt does PLYX have?
Polaryx Therapeutics Inc. reported $11.54M in cash and cash equivalents on its most recent balance sheet in SEC filings.Where does PLYX stock trade?
Polaryx Therapeutics Inc. (PLYX) is listed on NASDAQ.What sector and industry is PLYX in?
Polaryx Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about PLYX?
Polaryx Therapeutics Inc. has had 3 recent analyst actions on file. The most recent action was from Raymond James: Strong Buy with a $6.00 price target on 2026-08-13. Recent price targets range from $6.00 to $10.00.What companies are similar to PLYX?
Notable peers in the same industry include AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABT (Abbott Laboratories), MRK (Merck & Company Inc.), ABBV (AbbVie Inc.). Compare PLYX side-by-side with any of them on Quantisnow.How can I track PLYX on Quantisnow?
Quantisnow aggregates Polaryx Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow PLYX to receive live email and push alerts on every new disclosure.